Paeoniflorin‐6′‐O‐Benzenesulfonate Mediates Dendritic Cell Differentiation to Alleviate Diabetic Kidney Disease
Clinical and Experimental Pharmacology and Physiology · 2026
DOI: 10.1111/1440-1681.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2026. Verfasst von Wei Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, the Grade 3 Pharmaceutical Chemistry Laboratory of State Administr…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Monoterpenes, Dendritic Cells, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Outstanding Talent Cultivation Program for Universities of Department of Education of Anhui Province, Nature Science Foundation of Anhui Province of China.
Abstract (Originalsprache)
Aim
Recent studies demonstrated that the mature dendritic cells (DCs) exhibit renal pathogenicity and promote diabetic kidney disease (DKD). This study investigates the therapeutic potential and mechanisms of paeoniflorin‐6 ′ ‐O‐benzene sulfonate (CP‐25) to DCs in DKD.
Methods
DKD mouse model was established by high‐fat (HFD) feeding combined with intraperitoneal streptozotocin (STZ) injection. Renal histopathological changes were assessed via haematoxylin and eosin (H&E), masson, and periodic acid‐schiff (PAS) staining. Renal function, oxidative stress, and lipid were also quantified. Immune cell differentiation and function were analysed by flow cytometry (FCM). The expression of renal injury markers and fibrosis‐associated mRNA and proteins were evaluated by quantitative real‐time PCR (qPCR) and western blotting. The target G protein‐coupled receptor kinase 2 (GRK2), PI3K‐AKT–mTOR, and JAK2‐STAT3‐SOCS3 pathways were examined to analyse the mechanism of CP‐25 to DKD.
Results
CP‐25 alleviated renal histopathological damage, inflammatory infiltration, and fibrosis in DKD. CP‐25 also reversed renal function, lipid, and oxidative stress indicators of DKD. Additionally, CP‐25 inhibited pro‐inflammatory cytokines (IL‐12) and promoted anti‐inflammatory cytokines (IL‐4 and IL‐10) secretion in the serum of DKD. CP‐25 inhibited the differentiation of CD103 + DCs and the maturity of DCs in the bone marrow and kidney. Subsequently, CD8 + T cells in the spleen and kidney, NKT in the spleen, and T regs in the spleen and kidney of DKD mice were inhibited by CP‐25 treatment. Other immune cells in other immune organs were less affected by CP‐25. The communication of DC and T cell was down‐regulated by CP‐25. The specific mechanism involved CP‐25 targeting GRK2 to inhibit the JAK2‐STAT3‐SOCS3 pathway, thereby suppressing DC maturation and T cell communication in the renal inflammatory response to treat DKD. However, the inhibition of CP‐25 to PI3K was indistinctive.
Conclusion
CP‐25 exhibits therapeutic efficacy against kidney injury in DKD. Its primary mechanism involves modulating the differentiation and function of DCs, which affects the activation of T cells. In terms of mechanism, CP‐25 targets the GRK2‐mediated JAK2‐STAT3‐SOCS3 signalling pathway to inhibit inflammation for alleviating DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, the Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, China.
- Department of Pharmacy, Shanghai Hudong Hospital, Shanghai, China.
- Department of Ultrasound, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
- School of Pharmaceutical Sciences, Anhui Medical University, Hefei, China.
- Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Anhui Medical University, the Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center…
- School of Life Sciences, the Chinese University of Hong Kong; State Key Laboratory of Agrobiotechnology, the Chinese University of Hong Kong, Hong Kong, China.
ORCID-Profile: Chun Wang, Feng Xiao, Tingting Liu
Förderung
- National Natural Science Foundation of China
- Outstanding Talent Cultivation Program for Universities of Department of Education of Anhui Province
- Nature Science Foundation of Anhui Province of China
- Anhui Provincial Scientific Research Project on Traditional Chinese Medicine Inheritance and Innovation
- Anhui Provincial Quality Engineering Education Research Project
- Open Fund of Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, P.R. China
- Natural Science Foundation of Universities of Anhui Province
- Research Fund of Anhui Institute of Translational Medicine
Zitieren
APA
Liang, W., Zhu, D., Xiao, L., Wu, X., Zhang, H., Cao, L., Hu, M., Wang, C., Xiao, F., Wei, W., & Liu, T. (2026). Paeoniflorin‐6′‐O‐Benzenesulfonate Mediates Dendritic Cell Differentiation to Alleviate Diabetic Kidney Disease. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70124
Vancouver
Liang W, Zhu D, Xiao L, Wu X, Zhang H, Cao L, et al. Paeoniflorin‐6′‐O‐Benzenesulfonate Mediates Dendritic Cell Differentiation to Alleviate Diabetic Kidney Disease. Clinical and Experimental Pharmacology and Physiology. 2026. doi:10.1111/1440-1681.70124
BibTeX
@article{Liang2026,
author = {Liang, Wei and Zhu, Dongchun and Xiao, Lei and Wu, Xiaoqian and Zhang, Hongwei and Cao, Li and Hu, Mengxue and Wang, Chun and Xiao, Feng and Wei, Wei and Liu, Tingting},
title = {Paeoniflorin‐6′‐O‐Benzenesulfonate Mediates Dendritic Cell Differentiation to Alleviate Diabetic Kidney Disease},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2026},
doi = {10.1111/1440-1681.70124}
}
EUVIMED